Six Years And Four Trials Later, LABA/ICS Combos Twist Free Of Box Warning
Executive Summary
US FDA concludes that combination products do not increase risk of serious asthma-related events compared to inhaled corticosteroids alone.
You may also be interested in...
FDA Supersizes Its Order For LABA Safety Studies
The trials, which follow a label change and new REMS, will encompass seven times the patients included in the studies submitted to FDA for approval.
FDA Calls For Class-Wide REMS For LABA Asthma Drugs
On top of a class-wide Risk Evaluation and Mitigation Strategy for the long acting beta-2 adrenergic agonist class of asthma drugs, FDA is going to work through its Safe Use partners to monitor whether actual use adjusts based on the new safety measures
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.